Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Muneyoshi Futami, MD PhD, Keisuke Suzuki, MS, Satomi Kato, BS, Yoshio Tahara, MS, Yoichi Imai, MD PhD, Takayuki Mimura, PhD, Yoshihiro Watanabe, PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 2067.

https://doi.org/10.1182/blood-2019-129601

Published: 2019

Journal Articles

Effects of Targeting the Interleukin-1 Receptor in a Murine Model of Sickle Cell Disease

Jessica Venugopal, PhD, Jintao Wang, PhD, Chiao Guo, Daniel Eitzman, MD

Blood (2019) 134 (Supplement_1): 2259.

https://doi.org/10.1182/blood-2019-128980

Published: 2019

Journal Articles

CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS

Robin Sanderson, MRCP,FRCPath, Arantxa Romero-Toledo, MSc, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 249.

https://doi.org/10.1182/blood-2019-125647

Published: 2019

Journal Articles

Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome

Dorota M. Rowczenio, Shelly Pathak, Juan I. Arostegui, Anna Mensa-Vilaro, Ebun Omoyinmi, Paul Brogan, Dan Lipsker, Thomas Scambler, Roger Owen, Hadija Trojer, Anna Baginska, Julian D. Gillmore, Ashutosh D. Wechalekar, Thirusha Lane, Rene Williams, Taryn Youngstein, Philip N. Hawkins, Sinisa Savic, Helen J. Lachmann

Blood (2018) 131 (9): 974–981.

https://doi.org/10.1182/blood-2017-10-810366

Published: 2018

Includes: Supplemental data

Journal Articles

Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome

Nirali N Shah, MD, Haneen Shalabi, DO, Bonnie Yates, RN, Eli Kane, Alina Dulau-Florea, MD, Anne Cullinane, BS, Cynthia Delbrook, RN, Michael Ombrello, MD, Amanda Ombrello, MD, Jay Nelson Lozier, MD PhD, Terry J. Fry, MD

Blood (2017) 130 (Supplement 1): 1277.

https://doi.org/10.1182/blood.V130.Suppl_1.1277.1277

Published: 2017

Journal Articles

Development of Anti-IL-1R3 Monoclonal Antibodies for Treating Cancer and IL-1 Family-Mediated Inflammation

Jesper F Højen, MD, Megan K Taylor, Tania Azam, Stephan Fischer, Daniel A Pollyea, MD, Craig T Jordan, PhD, Charles A. Dinarello, MD

Blood (2016) 128 (22): 5224.

https://doi.org/10.1182/blood.V128.22.5224.5224

Published: 2016

Journal Articles

Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease

Eli L. Diamond, Omar Abdel-Wahab, Benjamin H. Durham, Ahmet Dogan, Neval Ozkaya, Lynn Brody, Maria Arcila, Christian Bowers, Mark Fluchel

Blood (2016) 128 (14): 1896–1898.

https://doi.org/10.1182/blood-2016-06-725143

Published: 2016

Journal Articles

Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease

Fleur Cohen-Aubart, Philippe Maksud, David Saadoun, Aurélie Drier, Frédéric Charlotte, Philippe Cluzel, Zahir Amoura, Julien Haroche

Blood (2016) 127 (11): 1509–1512.

https://doi.org/10.1182/blood-2015-09-672667

Published: 2016

Journal Articles

Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders

David M. Hyman, MD, Eli Diamond, Cecile Rose Vibat, Latifa Hassaine, Jason Poole, Minal Patel, Veronica Holley, Goran Cabrilo, Timothy T. Lu, Maria Arcila, MD, Young Rock Chung, MS, Raajit K. Rampal, MD PhD, Funda Meric-Bernstam, MD, Jose Baselga, MD PhD, Razelle Kurzrock, MD, Mark Erlander, Filip Janku, MD PhD, Omar Abdel-Wahab, MD

Blood (2014) 124 (21): 1833.

https://doi.org/10.1182/blood.V124.21.1833.1833

Published: 2014

Journal Articles

HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review

David C Fajgenbaum, MD MSc, Amy Liu, Jason Ruth, PhD, Chris Nabel, PhD, Brian Finkelman, BS, Razelle Kurzrock, MD, Frits van Rhee, MD PhD, Arthur Rubenstein, MBBCh

Blood (2014) 124 (21): 4861.

https://doi.org/10.1182/blood.V124.21.4861.4861

Published: 2014

Journal Articles

Interplay Between IL-1, IL-6 and IL-17 in IL-1 Receptor Antagonist (IL-1Ra) Treated Multiple Myeloma Patients

Kathleen A. Donovan, PhD, Laurie L. Moon-Tasson, BA, John A Lust, MD, PhD

Blood (2012) 120 (21): 1874.

https://doi.org/10.1182/blood.V120.21.1874.1874

Published: 2012

Journal Articles

Inflammatory Cytokines and Thrombosis

Thomas M. McIntyre, PhD

Blood (2012) 120 (21): SCI-44.

https://doi.org/10.1182/blood.V120.21.SCI-44.SCI-44

Published: 2012

Journal Articles

Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome

Evangelos Terpos, Bouchra Asli, MD, Dimitrios Christoulas, Jean-Claude Brouet, Efstathios Kastritis, Michel Rybojad, Meletios Athanasios Dimopoulos, MD, Jean Paul Fermand, MD

Blood (2011) 118 (21): 1802.

https://doi.org/10.1182/blood.V118.21.1802.1802

Published: 2011

Journal Articles

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

John A Lust, MD, PhD, Martha Q Lacy, MD, Steven R Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Morie A Gertz, MD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Shaji Kumar, MD, Laurie L. Moon-Tasson, BA, S. Vincent Rajkumar, MD, Kathleen A. Donovan, PhD

Blood (2011) 118 (21): 2945.

https://doi.org/10.1182/blood.V118.21.2945.2945

Published: 2011

Journal Articles

The Blood Monocyte - TNF - Endothelial Axis in Activation of Endothelial Tissue Factor in the Transgenic Sickle Mouse: Possible Relevance of Etanercept to Sickle Coagulopathy

Anna Solovey, M.D., Liming Milbauer Chang, Ph.D., Fuad Abdulla, Rahn Kollander, Paul H Marker, MS, Robert Kelm, Jr., Ph.D., Gregory M Vercellotti, MD, Robert P Hebbel, MD

Blood (2011) 118 (21): 1048.

https://doi.org/10.1182/blood.V118.21.1048.1048

Published: 2011

Journal Articles

Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases

Helen J Lachmann, MD, FRCP, Stephen Harding, PhD, Ashutosh Wechalekar, MD, FRCPath, Julian D Gillmore, E. Nicole Amft, MD, PhD, FRCP, Philip N Hawkins

Blood (2010) 116 (21): 3958.

https://doi.org/10.1182/blood.V116.21.3958.3958

Published: 2010

Journal Articles

Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease

Achille Aouba, Sophie Georgin-Lavialle, Christian Pagnoux, Nicolas Martin Silva, Amédée Renand, Françoise Galateau-Salle, Sophie Le Toquin, Henri Bensadoun, Frederique Larousserie, Stéphane Silvera, Nicole Provost, Sophie Candon, Raphaèle Seror, Mathilde de Menthon, Olivier Hermine, Loïc Guillevin, Boris Bienvenu

Blood (2010) 116 (20): 4070–4076.

https://doi.org/10.1182/blood-2010-04-279240

Published: 2010

Journal Articles

IL-1 Antagonists Are More Effective at Inhibiting IL-6 Production Than Apoptosis Inducing Agents: Implications for Targeting the Myeloma Proliferative Component.

John A. Lust, MD, PhD, Steven R. Zeldenrust, M.D., Ph.D., Laurie L. Moon-Tasson, Kathleen A. Donovan, Ph.D.

Blood (2009) 114 (22): 1831.

https://doi.org/10.1182/blood.V114.22.1831.1831

Published: 2009

Journal Articles

Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.

John A. Lust, MD, PhD, Martha Q. Lacy, MD, Steven R. Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Morie A. Gertz, MD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Shaji Kumar, MD, Susan M. Geyer, PhD, Laurie L. Moon-Tasson, S. Vincent Rajkumar, MD, Kathleen A. Donovan, PhD

Blood (2006) 108 (11): 3500.

https://doi.org/10.1182/blood.V108.11.3500.3500

Published: 2006

Journal Articles

In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.

John A. Lust, MD, PhD, Martha Q. Lacy, MD, Steven R. Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Morie A. Gertz, MD, Philip R. Greipp, MD, Thomas E. Witzig, MD, Susan M. Geyer, PhD, Laurie L. Moon-Tasson, S. Vincent Rajkumar, MD, Kathleen A. Donovan, PhD

Blood (2005) 106 (11): 2567.

https://doi.org/10.1182/blood.V106.11.2567.2567

Published: 2005

NARROW

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Effects of Targeting the Interleukin-1 Receptor in a Murine Model of Sickle Cell Disease

CAR T Cells Derived from Healthy Mice Lead to Cytokine Release Syndrome (CRS) in the TCL1 Chronic Lymphocytic Leukemia Model; Mice with CLL Treated with Acalabrutinib or Ibrutinib Have Improved CAR T Cell Function without Increasing the Cytokines of CRS

Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome

Beyond Cytokine Storm: Optimizing Treatment Strategies to Target the Complex Interplay between CAR Mediated Inflammatory Response, Disseminated Intravascular Coagulation and Macrophage Activation Syndrome

Development of Anti-IL-1R3 Monoclonal Antibodies for Treating Cancer and IL-1 Family-Mediated Inflammation

Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease

Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease

Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders

HHV-8-Negative, Idiopathic Multicentric Castleman Disease (iMCD): A Description of Clinical Features and Therapeutic Options through a Systematic Literature Review

Interplay Between IL-1, IL-6 and IL-17 in IL-1 Receptor Antagonist (IL-1Ra) Treated Multiple Myeloma Patients

Inflammatory Cytokines and Thrombosis

Increased Angiogenesis and Enhanced Bone Formation in Patients with IgM Monoclonal Gammopathy and Urticarial Skin Rash: New Insight Into the Biology of the Schnitzler Syndrome

Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component

The Blood Monocyte - TNF - Endothelial Axis in Activation of Endothelial Tissue Factor in the Transgenic Sickle Mouse: Possible Relevance of Etanercept to Sickle Coagulopathy

Remarkable Efficacy of IL-1 Receptor Antagonist In Schnitzler's Syndrome: a Series of 6 Cases

Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease

IL-1 Antagonists Are More Effective at Inhibiting IL-6 Production Than Apoptosis Inducing Agents: Implications for Targeting the Myeloma Proliferative Component.

Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.

In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only